MOULDER LEON O JR 4

What Happened
Leon O. Moulder Jr., Zenas BioPharma's Chief Executive Officer and a director, was granted a derivative award on June 15, 2026: options covering 500,000 shares of common stock. The grant shows an acquisition price of $0.00 (i.e., an option/award grant rather than a cash purchase). No immediate cash was exchanged and no exercise or sale of underlying shares is reported in this filing.

Key Details

• Transaction date: 2026-06-15; Form 4 filed: 2026-06-17 (timely filing).
• Transaction type/code: Award/Grant (derivative) — 500,000 options; reported price $0.00.
• Vesting (per footnote): 25% vests on June 15, 2027 (first anniversary), remaining shares vest in equal monthly installments over the next 36 months, subject to continued service.
• Shares owned after transaction: Not specified in the provided filing details.
• Filing timeliness: No late filing indicated.

Context
This is a typical executive compensation grant (option award). Because it’s a derivative grant, Moulder does not immediately own the underlying shares — ownership depends on future vesting and any subsequent exercise. The filing does not indicate exercise, sale, or tax-withholding actions tied to this grant.